JP2013545744A5 - - Google Patents

Download PDF

Info

Publication number
JP2013545744A5
JP2013545744A5 JP2013538312A JP2013538312A JP2013545744A5 JP 2013545744 A5 JP2013545744 A5 JP 2013545744A5 JP 2013538312 A JP2013538312 A JP 2013538312A JP 2013538312 A JP2013538312 A JP 2013538312A JP 2013545744 A5 JP2013545744 A5 JP 2013545744A5
Authority
JP
Japan
Prior art keywords
dimethoxyphenyl
benzyl
methyl
piperidin
pyrrolidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013538312A
Other languages
English (en)
Japanese (ja)
Other versions
JP5847830B2 (ja
JP2013545744A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2011/054993 external-priority patent/WO2012063207A1/en
Publication of JP2013545744A publication Critical patent/JP2013545744A/ja
Publication of JP2013545744A5 publication Critical patent/JP2013545744A5/ja
Application granted granted Critical
Publication of JP5847830B2 publication Critical patent/JP5847830B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013538312A 2010-11-10 2011-11-09 オレキシン受容体拮抗薬として有用なラクタム誘導体 Expired - Fee Related JP5847830B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IBPCT/IB2010/055105 2010-11-10
IB2010055105 2010-11-10
PCT/IB2011/054993 WO2012063207A1 (en) 2010-11-10 2011-11-09 Lactam derivatives useful as orexin receptor antagonists

Publications (3)

Publication Number Publication Date
JP2013545744A JP2013545744A (ja) 2013-12-26
JP2013545744A5 true JP2013545744A5 (enExample) 2014-12-11
JP5847830B2 JP5847830B2 (ja) 2016-01-27

Family

ID=45757741

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013538312A Expired - Fee Related JP5847830B2 (ja) 2010-11-10 2011-11-09 オレキシン受容体拮抗薬として有用なラクタム誘導体

Country Status (6)

Country Link
US (1) US9242970B2 (enExample)
EP (1) EP2638008B1 (enExample)
JP (1) JP5847830B2 (enExample)
CN (1) CN103201261A (enExample)
CA (1) CA2815179A1 (enExample)
WO (1) WO2012063207A1 (enExample)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
LT2855453T (lt) 2012-06-04 2017-02-27 Actelion Pharmaceuticals Ltd. Benzimidazolo prolino dariniai
HUE042374T2 (hu) 2012-06-13 2019-06-28 Incyte Holdings Corp Szubsztituált triciklusos vegyületek mint FGFR inhibitorok
NZ704171A (en) 2012-07-19 2017-10-27 Cayman Chemical Co Inc Difluorolactam compositions for ep4-mediated osteo related diseases and conditions
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
EP3763367A1 (en) 2012-12-06 2021-01-13 Celgene Quanticel Research, Inc. Pyridine-pyrazole derivatives as histone demethylase inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
US9914725B2 (en) 2013-03-15 2018-03-13 Cayman Chemical Company, Inc. Methods of synthesizing a difluorolactam analog
EA201591793A1 (ru) 2013-03-15 2016-01-29 Кайман Кемикал Компани, Инк. Лактамные соединения в качестве селективных агонистов ep4-рецепторов для применения при лечении опосредованных ep4 заболеваний и состояний
US9676712B2 (en) 2013-03-15 2017-06-13 Cayman Chemical Company, Inc. Lactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions
KR102469849B1 (ko) 2013-04-19 2022-11-23 인사이트 홀딩스 코포레이션 Fgfr 저해제로서 이환식 헤테로사이클
CN104133004A (zh) * 2013-05-03 2014-11-05 上海美迪西生物医药有限公司 血浆样品中2,3-吲哚醌的浓度的测定方法
CA2910398A1 (en) 2013-07-19 2015-01-22 Cayman Chemical Company, Inc. Methods, systems, and compositions for promoting bone growth
PT3077389T (pt) 2013-12-03 2017-12-15 Idorsia Pharmaceuticals Ltd Forma cristalina de (s)-(2-(6-cloro-7-metil-1hbenzo[d]imidazol-2-il)-2-metilpirrolidin-1-il)(5-metoxi-2-(2h-1,2,3-triazol-2-il)fenil)metanona e a sua utilização como como antagonistas do receptor de orexina
UA119151C2 (uk) 2013-12-03 2019-05-10 Ідорсія Фармасьютікалз Лтд КРИСТАЛІЧНА СОЛЬОВА ФОРМА (S)-(2-(6-ХЛОР-7-МЕТИЛ-1H-БЕНЗО[d]ІМІДАЗОЛ-2-ІЛ)-2-МЕТИЛПІРОЛІДИН-1-ІЛ)(5-МЕТОКСИ-2-(2H-1,2,3-ТРИАЗОЛ-2-ІЛ)ФЕНІЛ)МЕТАНОНУ ЯК АНТАГОНІСТ ОРЕКСИНОВОГО РЕЦЕПТОРА
SI3077391T1 (sl) 2013-12-04 2018-11-30 Idorsia Pharmaceuticals Ltd Uporaba benzimidazol-prolinskih derivatov
WO2015088864A1 (en) * 2013-12-09 2015-06-18 Merck Sharp & Dohme Corp. 2-pyridyloxy-3-ester-4-ether orexin receptor antagonists
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
AU2016219822B2 (en) 2015-02-20 2020-07-09 Incyte Holdings Corporation Bicyclic heterocycles as FGFR inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
WO2016134294A1 (en) 2015-02-20 2016-08-25 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
CA3027500A1 (en) * 2016-06-21 2017-12-28 X4 Pharmaceuticals, Inc. Cxcr4 inhibitors and uses thereof
EP3808748A1 (en) 2016-06-21 2021-04-21 X4 Pharmaceuticals, Inc. Substituted piperidines as cxcr4-inhibitors
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
US11434201B2 (en) * 2017-08-02 2022-09-06 Vertex Pharmaceuticals Incorporated Processes for preparing pyrrolidine compounds
EP4309737A3 (en) 2018-05-04 2024-03-27 Incyte Corporation Solid forms of an fgfr inhibitor and processes for preparing the same
EP3788046B1 (en) 2018-05-04 2025-12-10 Incyte Corporation Salts of an fgfr inhibitor
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
CN110563565A (zh) * 2019-09-02 2019-12-13 南通大学 一种3-溴-6-氟-2-甲氧基苯甲醛的合成方法
US12122767B2 (en) 2019-10-01 2024-10-22 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
WO2021076602A1 (en) 2019-10-14 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
JP7720840B2 (ja) 2019-12-04 2025-08-08 インサイト・コーポレイション Fgfr阻害剤としての三環式複素環
KR20220131900A (ko) 2019-12-04 2022-09-29 인사이트 코포레이션 Fgfr 억제제의 유도체
US12012409B2 (en) 2020-01-15 2024-06-18 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
CA3215903A1 (en) 2021-04-12 2022-10-20 Incyte Corporation Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
WO2022261159A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
EP4352059A1 (en) 2021-06-09 2024-04-17 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
CN114456184B (zh) * 2022-02-21 2023-08-22 南华大学附属第一医院 一种3-芳基异喹啉衍生物及其制备与应用
CN115047127B (zh) * 2022-04-25 2024-03-08 中国检验检疫科学研究院 一种利用挥发性代谢组学技术鉴别nfc和fc橙汁的方法
TW202409023A (zh) 2022-07-14 2024-03-01 美商富曼西公司 除草苯并𠯤
WO2025111184A1 (en) 2023-11-21 2025-05-30 Fmc Corporation Substituted tetrahydroquinoline and tetrahydroquinoxaline herbicides
WO2025224168A1 (en) 2024-04-24 2025-10-30 Idorsia Pharmaceuticals Ltd Aryl sulfone and sulfanone derivatives as orexin receptor modulators

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0115862D0 (en) * 2001-06-28 2001-08-22 Smithkline Beecham Plc Compounds
EP1537089A4 (en) * 2002-07-23 2008-04-16 Cytokinetics Inc CONNECTIONS, COMPOSITIONS AND PROCEDURES
HRP20150371T1 (hr) 2004-03-01 2015-05-08 Actelion Pharmaceuticals Ltd. Supstituirani derivati 1,2,3,4-tetrahidroizokinolina
EP1888563A1 (en) * 2005-05-23 2008-02-20 Merck & Co., Inc. Proline bis-amide orexin receptor antagonists
AU2007226203A1 (en) 2006-03-15 2007-09-20 Actelion Pharmaceuticals Ltd Tetrahydroisoquinoline derivatives to enhance memory function
PL2069332T3 (pl) * 2006-08-15 2011-07-29 Actelion Pharmaceuticals Ltd Związki azetydynowe jako antagoniści receptorów oreksynowych
EP2079690B1 (en) * 2006-09-29 2010-09-15 Actelion Pharmaceuticals Ltd. 3-aza-bicyclo[3.1.0]hexane derivatives
CL2008000836A1 (es) * 2007-03-26 2008-11-07 Actelion Pharmaceuticals Ltd Compuestos derivados de tiazolidina, antagonistas del receptor de orexina; composicion farmaceutica que los comprende; y su uso en el tratamiento de neurosis emocional, depresion grave, trastornos psicoticos, alzheimer, parkinson, dolor, entre otras.
EA201070091A1 (ru) * 2007-07-03 2010-06-30 Глэксо Груп Лимитед Производные пиперидина, пригодные в качестве антагонистов рецептора орексина
CA2694993A1 (en) * 2007-08-15 2009-02-19 Actelion Pharmaceuticals Ltd 1,2-diamido-ethylene derivatives
EP2207778A2 (en) * 2007-09-24 2010-07-21 Actelion Pharmaceuticals Ltd. Pyrrolidines and piperidines as orexin receptor antagonists
PE20091010A1 (es) 2007-10-10 2009-08-08 Actelion Pharmaceuticals Ltd Derivados de tetrahidroquinolina
CA2722347A1 (en) * 2008-04-30 2009-11-05 Actelion Pharmaceuticals Ltd Piperidine and pyrrolidine compounds
JP2011522878A (ja) * 2008-06-11 2011-08-04 アクテリオン ファーマシューティカルズ リミテッド オレキシン受容体拮抗薬としてのテトラゾール化合物
CA2739919A1 (en) * 2008-10-21 2010-04-29 Merck Sharp & Dohme Corp. 2,4-disubstituted pyrrolidine orexin receptor antagonists
US20120088759A1 (en) 2009-05-12 2012-04-12 Hamed Aissaoui Thiazolidin-4-one and [1,3]-thiazinan-4-one compounds as orexin receptor antagonists
JP5612080B2 (ja) 2009-05-12 2014-10-22 アクテリオン ファーマシューティカルズ リミテッドActelion Pharmaceuticals Ltd 新規なオキサゾリジノン誘導体

Similar Documents

Publication Publication Date Title
JP2013545744A5 (enExample)
IL258577A (en) 2,4-dihydroxy-nicotinamides as apj agonists
JP2018530591A5 (enExample)
RU2396269C2 (ru) Производные гетероарилзамещенного пиперидина в качестве ингибиторов печеночной карнитин пальмитоилтрансферазы (l-cpt1)
RU2010137300A (ru) Модуляторы бета-амилоида
JP2011503166A5 (enExample)
RU2012105284A (ru) Спиро-аминосоединения, пригодные для лечения нарушений сна и лекарственного привыкания
ME02437B (me) Disupstituirani oktahidropirolo[3,4-c]piroli kao modulatori oreksin receptora
JP2010508338A5 (enExample)
JP2016145215A5 (enExample)
JP2007523208A5 (enExample)
HRP20250632T1 (hr) Nlrp3 inhibitori
JP2013515032A5 (enExample)
IL187690A (en) Derivatives 1, 2, 4 - Triazolo - 1, 6 - Naphthiridines as inhibitors of AKT activity for use in the preparation of drugs for the treatment of cancer
JP2013544873A5 (enExample)
HRP20120281T1 (hr) Derivati azabiciklo[3.1.0]heksana, korisni kao modulatori dopaminskih receptora d3
RU2009121564A (ru) Азаадамантановые производные и способы применения
RU2015132181A (ru) Фтор-[1,3]-оксазины в качестве ингибиторов васе1
JP2006506352A5 (enExample)
JP2015521999A5 (enExample)
JP2013508403A5 (enExample)
JP2014516073A5 (enExample)
JP2020516671A5 (enExample)
JP2017502049A5 (enExample)
CA2642922A1 (en) Melanocortin type 4 receptor agonist piperidinoylpyrrolidines